The umbrella organization of the Israeli high-tech and life science industry has proved irresponsible and has damaged the claim of a team of Israeli researchers that they have developed a concept that will pave the way to cancer treatment.
The great public that created a seeming breakthrough that, as the Times of Israel noted, was not published for peer reviews in medical journals and that overseas experts have claimed is likely to be wrong, damages Israel Reputation in the field of life sciences, said the Israeli umbrella group.
"We welcome all companies developing breakthrough technologies," said Karin Mayer Rubinstein, CEO of Israel Advanced Technology Industries (IATI), on Thursday of the Times of Israel. However, she warned, "Researchers' statements have damaged the image of the Israeli life sciences industry." IATI is the umbrella organization, the Israeli high-tech and life science companies, VCs, multinationals, incubators and Israeli companies active in Israel Technology company represents transfer arms of the Israeli Academy.
"It is a very irresponsible statement, and we have asked many people from around the world to clarify the issue," she said. "As we understand, there are critical research phases that still need to be fulfilled. These kinds of statements can hurt Israel's life science industry, which is globally positioned as one of the world's most serious and professional. "
" Israel's life science industry consists for the most part of very serious individuals with a high proportion of experience. We expect them to behave more responsibly, especially before they make such statements, "said Mayer Rubinstein. She noted that she was "asked by Israeli life science industry executives to clarify our position on the matter."
The information on cancer healing was provided by researchers at Nes Ziona-based Startup Accelerated Evolution Biotechnologies Ltd. (AEBi), to the Jerusalem Post earlier this week. The company's CEO repeated the allegations in an interview with the Times of Israel on Wednesday, but admitted that his research had not been published in respected medical journals as the company "could not afford it."
The Times of Israel has turned to numerous hospitals and experts in Israel to try to assess the claims of a dramatic breakthrough however, refused to comment and some stated that they had no direct information about the research. However, other overseas experts stated clear warnings of the researchers' claims and dismissed them as unreliable.
Dr. Ben Neel, director of the Perlmutter Cancer Center at NYU Langone Health, told The New York Post that "cancer is multiple diseases and it is highly unlikely that this company has found a 'cure' for cancer when there is a single cure Infections. "He said," more likely this claim is another in a long line of false, irresponsible and ultimately cruel false promises for cancer patients. "
Ilan Morad, the CEO and founder of AEBi, told the Times of Times Israel said On Thursday, the reaction of critics who have not seen the company's results is "How to criticize a book without reading it".
He reiterated that the company could treat patients in clinical trials that "should start quite quickly" and clarified: "We do not say that the drug will be approved in one year. Our technology is innovative and we have a patent pending. This application is at an advanced stage, and so far the patent attorneys have considered our technology innovative. "
" We are working on a complete cure for cancer, "Morad said in an interview with the Times of Israel on Wednesday. The company's demands to the Jerusalem Post were reiterated earlier this week." We still have a long way to go us, but in the end we believe that we will have a cure for all types of cancer patients and with very few side effects. "Morad told the Times of Israel that the company has not published its research in medical journals, as it has the norm is because it "can not afford" but that the results of preclinical studies were "very good."
"We are a small company," he said. "Publishing an article takes a lot of effort and money, and we can not afford it." He added, "If we were a big company with a lot of money, we would do it first. If I have $ 100,000, what do I spend it on? ", Asked he. "Driving research and finding more and more target peptides or performing many experiments to write an article? What would you do if you had to decide?
In the conventional development process, medical researchers making a discovery collect their material and submit a paper to legitimize medical journals in the hope that journal editorial boards will do so validating their findings and publishing the discovery. The higher the reputation of the publication, the greater the apparent value of the discovery. Researchers do not have to pay for legitimate medical journals to publish their findings.